Icon
Icon plc, headquartered in Ireland (IE), is a leading global provider of outsourced development and commercialisation services to the pharmaceutical, biotechnology, and medical device industries. Founded in 1990, Icon has established itself as a key player in the clinical research sector, with a strong presence across North America, Europe, and Asia. The company offers a comprehensive range of services, including clinical trial management, data analytics, and regulatory consulting, distinguished by its commitment to innovation and quality. Icon's unique approach integrates advanced technology and deep industry expertise, enabling clients to navigate the complexities of drug development efficiently. With a robust portfolio and a reputation for excellence, Icon plc has achieved significant milestones, including numerous successful product launches and partnerships with leading healthcare organisations, solidifying its position as a trusted partner in the life sciences industry.
DitchCarbon Score
How does Icon's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Icon's score of 55 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Icon's reported carbon emissions
In 2023, ICON plc reported total carbon emissions of approximately 44,770,000 kg CO2e. This includes 2,503,000 kg CO2e from Scope 1 emissions, 13,663,000 kg CO2e from Scope 2 emissions, and a significant 28,605,000 kg CO2e from Scope 3 emissions, primarily attributed to business travel. ICON has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its entire value chain by 2050. The company has established near-term targets to reduce absolute Scope 1 and 2 emissions by 61.2% by 2028, using a 2019 baseline. Additionally, it plans to cut absolute Scope 3 emissions by 20% by 2028, based on 2022 figures. Long-term goals include a 90% reduction in both Scope 1 and 2 emissions by 2050, and a similar 90% reduction in Scope 3 emissions by the same year. These targets align with the Science Based Targets initiative (SBTi) and reflect ICON's commitment to addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 1,827,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 18,796,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 36,726,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Icon is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
